Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer
Predicting Efficacy of Preoperative Immunotherapy Combined Treatment in Advanced Gastric Cancer
Ruijin Hospital
120 participants
Jun 17, 2025
OBSERVATIONAL
Conditions
Summary
This study intends to employ FAPI and Grazytracer PET/CT to predict the therapeutic response to preoperative immunotherapy-based combination regimens in patients with advanced gastric cancer. The study is expected to provide an early, non-invasive predictive tool for immunotherapy-based combination therapy in gastric cancer, offer molecular imaging-based evidence for treatment stratification, and facilitate the optimization of precision therapeutic strategies.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A FAP-targeted radiotracer for PET/CT imaging; administered intravenously.
A Granzyme B-targeted radiotracer for PET/CT imaging; administered intravenously.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07824479